Skip to main content
. Author manuscript; available in PMC: 2014 May 12.
Published in final edited form as: Biopharm Drug Dispos. 2013 Sep 12;34(8):442–451. doi: 10.1002/bdd.1860

Figure 1.

Figure 1

a. Comparisons of CsA apparent oral clearance (CL/F, adjusted for dose and weight) for PI−, EFV−, NVP−, PI+EFV−, PI+NVP− and nonHIV transplant subjects [18, 26] averaged over the first 3 months (weeks 2- and 12) post transplant, and the next 18 months (weeks 24, 52 and 104).

b. Comparisons of CsA apparent oral volume of distribution (V/F, adjusted for dose and weight) for PI−, EFV−, NVP−, PI+EFV−, PI+NVP− and nonHIV transplant subjects [18, 26] averaged over the first 3 months (weeks 2- and 12) post transplant, and the next 18 months (weeks 24, 52 and 104).